Aarti Drugs FY26 BRSR: PTSCL Unit Closure and Escalated ESG Capex
Aarti Drugs Ltd · Others (Uncategorized) · 03 Sept 2026, 3:26 am
Aarti Drugs FY26 BRSR: PTSCL Unit Closure and Escalated ESG Capex Aarti Drugs reported FY26 turnover of ₹2,26,038.50 lakhs and net worth of ₹1,40,479.08 lakhs, with exports driving 38% of revenue. A material regulatory event occurred on 9th Sep'25 when the Maharashtra Pollution Control Board mandated the closure of the chlorosulfonation process at the PTSCL unit following an HCl gas leak, halting production of that specific product. The company increased ESG-focused investments, allocating 15% of total capex and 27% of R&D to environmental improvements. Additionally, 10 of its 12 API manufacturing facilities now operate on Zero Liquid Discharge systems.
Original exchange filing (PDF)
More announcements from Aarti Drugs Ltd
- Intimation of sad demise of Promoter and Chairman Emeritus of the Company · 16 Nov 2026
- Transcript of Q2&H1 FY27 Earning Conference call · 11 Nov 2026
- Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requireents) Regulations, 2015 · 06 Nov 2026
- Audio recording for conference call for Analyst and Investors · 05 Nov 2026
- Investor Presentation for Q2 FY27 · 04 Nov 2026
- Press release on Financial results for Quarter and Half year ended September 2026 · 04 Nov 2026
- Financial Results for the quarter and half year ended September 30, 2026 · 04 Nov 2026
- Aarti Drugs Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 04 Nov 2026
